PAIN TRIGGERS
Medication causes loss of creativity, spontaneity, and emotional blunting.
Severe side effects from various ADHD medications limit treatment options.
SaaS· individuals with ADHDPain 8.00/10WTP 6.0/10Market 8.0/10Validation 9.0Confidence 95%Oct 1, 2026
DoseTune: Personalized ADHD Medication & Cognitive Side-Effect Tracker
Current ADHD medications create a painful trade-off between focus and functionality versus emotional expression, spontaneity, and creative spark, leaving users without systematic ways to optimize dosages or communicate qualitative side effects to clinicians.
analyticshealthcaremental-healthmobile-appproductivitysaas
1
STAGE 01 · PROBLEM
Is the problem real?
CANONICAL PROBLEM
ADHD medications (such as atomoxetine or stimulants) improve productivity and routine management but dull creativity, spontaneity, and emotional expression, making individuals feel less like themselves.
FREQUENCY
Multiple repeated complaints in the post and comments.
INTENSITY
Users explicitly describe existing tools as bloated/overkill and mention workaround behavior.
EVIDENCE
ADHD Spark is gone
ADHD63
ADHD Spark is gone
ADHD63
2
STAGE 02 · CUSTOMER
Who feels this pain?
TARGET USERS
individuals with ADHDA D H D Medication Users & Creatives
Adults with ADHD tracking medication efficacy against emotional blunting, creativity loss, and side effects.
Context
Maintain necessary focus and functionality for daily life without sacrificing creativity, emotional expression, and personal identity.
Experimenting with multiple different medications and dosages over an extended period (e.g., 8 months) to find a tolerable balance.
Considering stopping medication entirely due to the emotional toll and loss of identity.
Current Workarounds
experimenting with multiple different medications and dosages over many months
keeping unstructured notes or memory logs about daily mood and focus
considering stopping medication entirely due to identity loss
3
STAGE 03 · MARKET
Where's the gap?
EXISTING SOLUTION GAPS
Current medication options present a difficult trade-off between functionality/focus and personality/creativity.
Stimulants cause severe side effects like anger and heart palpitations, while non-stimulants like atomoxetine can cause emotional blunting.
OPPORTUNITY & VALUE
Why Now
Repeated complaints about emotional blunting, loss of creativity, and severe side effects forcing difficult choices between functionality and personality.
Value Proposition
Purpose-built for qualitative side effects like emotional blunting and creativity loss rather than standard medical compliance logging.
Product Direction
A specialized tracking and journaling tool designed for ADHD medication users to log daily creativity, emotional state, and focus metrics, generating longitudinal insights to share with psychiatrists for precise dosage adjustments.
4
STAGE 04 · BUSINESS
How does it make money?
MONETIZATION
$9/moIndividual pro plan · monthly billing
Model
SaaS subscription
WILLINGNESS TO PAY
Users spend hundreds of dollars on medications and months of trial-and-error; $9/mo is a low-friction investment to salvage their creativity and mental health.
5
STAGE 05 · EXECUTION
How do you ship it?
MVP PLAN
“Balance your focus without losing your spark in 6 weeks.”
A specialized tracking and journaling tool designed for ADHD medication users to log daily creativity, emotional state, and focus metrics, generating longitudinal insights to share with psychiatrists for precise dosage adjustments.
Core Features
Daily micro-logging for focus, creativity, and emotional expression
Longitudinal visualization comparing dosage changes against side-effect patterns
Clinician-ready report export summarizing efficacy versus personality trade-offs
Weekly Roadmap
1
W1-W2
Core daily side-effect and creativity logging framework operational.
- •Build mobile-first daily check-in flow
- •Define metrics for focus, creativity, and emotional blunting
- •Set up secure local and cloud user data storage
2
W3-W4
Analytics dashboard and clinician report generation functional.
- •Develop longitudinal correlation charts for dosage vs. creativity
- •Build PDF export view summarizing trends for psychiatrist visits
- •Implement reminder notifications for daily check-ins
3
W5
Stripe billing integration and private beta testing with 10 ADHD users.
- •Integrate Stripe subscription checkout
- •Onboard 10 beta testers from ADHD communities
- •Gather feedback on logging friction and insight usefulness
4
W6
Public launch across relevant digital communities.
- •Launch post on r/ADHD and related support spaces
- •Publish onboarding guide and privacy overview
- •Monitor initial conversion and retention metrics
Launch Strategy
Target ADHD support and advocacy communities on Reddit (r/ADHD, r/ADHD_Programmers) and X
RISKS & ASSUMPTIONS
Top Risks
Daily logging fatigue
Users with ADHD often struggle to maintain consistent daily tracking habits over long periods.
Medical regulatory boundaries
Providing insights around prescription medications requires careful wording to avoid unauthorized medical advice claims.
Low willingness to pay for self-care apps
Consumers can be hesitant to subscribe to wellness tools without immediate, tangible therapeutic outcomes.
6
STAGE 06 · DECISION
Should you build it?
NEED A CLEARER CALL?
Run an Investment Memo to get a structured Go / No-Go verdict, competitor landscape, unit economics, and a 90-day validation roadmap for this opportunity.
Generate an investment memoWhat this score means
This opportunity scores well above the median for ideas surfaced by MonetScope, with a validation sub-score of 9/10 against 3 independently sourced evidence signals. A "strong" rating in this band typically means the pain signal is consistent and recurring across multiple discussions, but one of the three pillars (severity, willingness to pay, or competitor weakness) is somewhat softer than top-tier opportunities. Founders evaluating this should focus customer discovery on the softest pillar first — confirming the gap before committing engineering time to a build.
Why this matters for SaaS founders
It sits at the intersection of "analytics", "healthcare", "mental-health", which makes it relevant to a specific subset of founders rather than a generic horizontal opportunity. SaaS opportunities at this stage tend to win on the strength of their initial wedge — a single workflow that the target user runs every week, where the existing solution is either spreadsheets, a clunky incumbent feature, or a manual process they hate. The build cost is moderate; the distribution cost is everything. The MonetScope pipeline surfaces this category alongside other saas signals, which is why it appears here rather than in a generic "trending ideas" feed.
Scores are derived from real forum discussions across Reddit, Hacker News and X, weighted by evidence volume and signal quality. How scoring works
Frequently asked questions
Is "DoseTune: Personalized ADHD Medication & Cognitive Side-Effect Tracker" a real validated startup idea or just an AI-generated suggestion?
MonetScope does not generate ideas from a language model's imagination. Every opportunity on this site is anchored to specific source posts and comments from real public discussions — typically on Reddit, Hacker News, or X — where actual users describe the pain in their own words. The AI's role is structuring, scoring, and grouping those signals into a navigable opportunity, not inventing the problem.
How recent is the underlying data for analytics?
MonetScope's spider pipeline runs continuously and surfaces opportunities as new evidence accumulates. The "Updated" date in the header reflects the most recent re-scoring of this specific opportunity. Most saas opportunities visible in the public catalog draw from discussions in the last 30-60 days; older signals are de-prioritized because user pain shifts faster than most founders assume.
What's the difference between "overall score" and "validation score"?
Overall score is a composite across six dimensions — pain, urgency, willingness to pay, market size, defensibility, and execution ease — designed to give a single number for triage. Validation score is narrower: it asks "how cleanly does the same signal repeat across independent sources?" An opportunity can score high on overall but lower on validation when one or two large discussions dominate the evidence; conversely, validation can be high on a smaller-overall idea where the signal is consistent but the addressable market is modest.